SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Mark J. Stillman, Stewart Tepper, Deborah E. Tepper, Leslie Cho, QT Prolongation, Torsade de Pointes, Myocardial Ischemia From Coronary Vasospasm, and Headache Medications. Part 1: Review of Serotonergic Cardiac Adverse Events With a Triptan Case, Headache: The Journal of Head and Face Pain, 2013, 53, 1
  2. 2
    Saurabh Gupta, Stephanie J. Nahas, B. Lee Peterlin, Chemical Mediators of Migraine: Preclinical and Clinical Observations, Headache: The Journal of Head and Face Pain, 2011, 51, 6
  3. 3
    Lars Neeb, Jannis Meents, Uwe Reuter, 5-HT1F receptor agonists: A new treatment option for migraine attacks?, Neurotherapeutics, 2010, 7, 2, 176

    CrossRef

  4. 4
    S. Lugardon, H. Roussel, V. Sciortino, J. L. Montastruc, M. Lapeyre-Mestre, Triptan use and risk of cardiovascular events: a nested-case-control study from the French health system database, European Journal of Clinical Pharmacology, 2007, 63, 8, 801

    CrossRef

  5. 5
    ANTHONY J. TOMASSONI, CARL A. GERMANN, Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, 2007,

    CrossRef

  6. 6
    Sen Devadathan, Mark Gunning, Atrial fibrillation following oral sumatriptan administration, International Journal of Cardiology, 2006, 107, 1, 112

    CrossRef

  7. 7
    Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, 2006,

    CrossRef

  8. 8
    Vincent T. Martin, James A. Goldstein, Evaluating the safety and tolerability profile of acute treatments for migraine, The American Journal of Medicine Supplements, 2005, 118, 36

    CrossRef

  9. 9
    Angelica Wackenfors, Malin Jarvius, Richard Ingemansson, Lars Edvinsson, Malin Malmsj??, Triptans Induce Vasoconstriction of Human Arteries and Veins from the Thoracic Wall, Journal of Cardiovascular Pharmacology, 2005, 45, 5, 476

    CrossRef

  10. 10
    David W. Dodick, Vincent T. Martin, Timothy Smith, Stephen Silberstein, Cardiovascular Tolerability and Safety of Triptans: A Review of Clinical Data, Headache: The Journal of Head and Face Pain, 2004, 44,
  11. 11
    Michael A. Crouch, Lynn Limon, Angela T. Cassano, Clinical Relevance and Management of Drug-Related QT Interval Prolongation, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003, 23, 7
  12. 12
    Dara G Jamieson, The safety of triptans in the treatment of patients with migraine, The American Journal of Medicine, 2002, 112, 2, 135

    CrossRef

  13. 13
    Randolph W. Evans, John F. Rothrock, Migraine Aura Without Headache Versus Transient Ischemic Attack During Pregnancy, Headache: The Journal of Head and Face Pain, 2001, 41, 4
  14. 14
    Frances Wilkinson, Migraine, Eating Disorders, and Triptans: An Unrecognized Risk?, Headache: The Journal of Head and Face Pain, 2001, 41, 9
  15. 15
    Frances Wilkinson, Migraine, Eating Disorders, and Triptans: An Unrecognized Risk?, Headache: The Journal of Head and Face Pain, 2001, 41, 9, 914

    CrossRef

  16. 16
    R. Verhaeghe, 2001,

    CrossRef

  17. 17
    Randolph W. Evans, Vincent Martin, Assessing Cardiac Risk Prior to Use of Triptans, Headache: The Journal of Head and Face Pain, 2000, 40, 7
  18. 18
    Current Awareness, Pharmacoepidemiology and Drug Safety, 2000, 9, 1